Akeso says its closely-watched lung cancer drug has definitively demonstrated for the first time that it could help some patients live longer, potentially boosting its prospects for approval in the US https://t.co/qtXfv9b5bp ...

Boehringer Ingelheim won approval in the US for its drug to treat a challenging form of lung cancer, offering a growth avenue for the privately-held German pharmaceuticals company https://t.co/cUaxU942wZ ...

jump there. Now, we've got more news on Astroenica. We were talking about this a few days ago.Angelica Peeles has the details for us. Hi, Angelica. Hey there.That's right. So, Bloomberg is reporting that Astroenica is in talks with Summit Therapeutics to license the company's experimental lung cancer drug for up to $15 billion. Now, Bloomberg is attributing this to people familiar with the matter.Now, this has been an incredibly hot area of development. Summit has really um shephered this whole field. this ...